Apotex Health Corp. (TSX:APTX)
Canada · Delayed Price · Currency is CAD 31.87
-0.50 (-1.54%)
At close: Aug 28, 2026
Apotex Health Cash Flow Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Net Income | -27.27 | 373.78 | 151.7 | -146.92 |
Depreciation & Amortization | 159.13 | 149.4 | 136.54 | 150.75 |
Other Amortization | 12.56 | 13.13 | 12.05 | 7.72 |
Loss (Gain) From Sale of Assets | 2.16 | 2.16 | -1.59 | -4.39 |
Asset Writedown & Restructuring Costs | 78.11 | 72.28 | 8.02 | - |
Stock-Based Compensation | 148.98 | 64.65 | 73.48 | 53.48 |
Other Operating Activities | -124.54 | -135.77 | 62.13 | 138.26 |
Change in Accounts Receivable | 90.98 | 31.4 | -104.97 | -24.05 |
Change in Inventory | -13.73 | 44.39 | -58.1 | 310.51 |
Change in Accounts Payable | 151.17 | 51.2 | 42.29 | 76.91 |
Change in Other Net Operating Assets | -218.23 | -25.64 | 232.88 | 8.64 |
Operating Cash Flow | 263.66 | 640.96 | 554.41 | 570.9 |
Operating Cash Flow Growth | - | 15.61% | -2.89% | - |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Capital Expenditures | -139.41 | -121.06 | -93.58 | -83.26 |
Sale of Property, Plant & Equipment | 4.9 | 4.9 | 16.7 | - |
Cash Acquisitions | - | - | -400.48 | -2,586 |
Sale (Purchase) of Intangibles | -69.98 | -60.91 | -150.51 | -28.27 |
Investing Cash Flow | -204.48 | -177.07 | -627.87 | -2,697 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Long-Term Debt Issued | - | 968.51 | 717.69 | - |
Long-Term Debt Repaid | - | -138.53 | -87.2 | -82.94 |
Net Debt Issued (Repaid) | 320.05 | 829.98 | 630.48 | -82.94 |
Issuance of Common Stock | 850 | - | - | 13.42 |
Repurchase of Common Stock | -140.95 | -140.95 | -745.72 | -200 |
Common Dividends Paid | -1,110 | -1,110 | -163.95 | - |
Other Financing Activities | -116.5 | -62.86 | - | -12.15 |
Financing Cash Flow | -197.03 | -483.46 | -279.19 | -281.67 |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Foreign Exchange Rate Adjustments | 6.51 | -1.41 | 9.26 | 3.33 |
Net Cash Flow | -131.34 | -20.98 | -343.38 | -2,405 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Free Cash Flow | 124.25 | 519.9 | 460.84 | 487.65 |
Free Cash Flow Growth | - | 12.82% | -5.50% | - |
Free Cash Flow Margin | 3.89% | 14.89% | 13.76% | 16.58% |
Free Cash Flow Per Share | 0.64 | 2.69 | 2.43 | 2.73 |
Levered Free Cash Flow | - | 468.34 | 487.86 | - |
Unlevered Free Cash Flow | - | 614.99 | 621.39 | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Cash Interest Paid | 215.16 | 207.07 | 156.85 | 107.98 |
Cash Income Tax Paid | 146.65 | 179.85 | 273.66 | 111.6 |
Change in Working Capital | 10.19 | 101.34 | 112.1 | 372.01 |